STAAR Surgical Company (STAA) Lowered to Hold at Zacks Investment Research
STAAR Surgical Company (NASDAQ:STAA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Friday.
According to Zacks, “Staar Surgical Company has evolved to become a developer, manufacturer and global distributor of products used by ophthalmologists and other eye care professionals to improve or correct vision in patients suffering from refractive conditions, cataracts and glaucoma. “
Other equities research analysts have also issued research reports about the company. TheStreet raised STAAR Surgical from a “d+” rating to a “c” rating in a research note on Tuesday, August 15th. BidaskClub raised STAAR Surgical from a “strong sell” rating to a “sell” rating in a research note on Friday, August 11th. Canaccord Genuity lifted their price objective on STAAR Surgical from $9.00 to $11.00 and gave the company a “hold” rating in a research note on Thursday, August 3rd. Finally, Benchmark Co. lifted their price objective on STAAR Surgical from $12.00 to $13.00 and gave the company a “buy” rating in a research note on Monday, August 14th. Three equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. STAAR Surgical has a consensus rating of “Hold” and an average target price of $12.00.
STAAR Surgical (STAA) opened at 10.85 on Friday. The firm’s market cap is $446.02 million. STAAR Surgical has a 12-month low of $7.45 and a 12-month high of $12.35. The stock’s 50 day moving average price is $11.51 and its 200-day moving average price is $10.28.
STAAR Surgical (NASDAQ:STAA) last posted its quarterly earnings results on Wednesday, August 2nd. The medical instruments supplier reported ($0.01) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.05) by $0.04. STAAR Surgical had a negative return on equity of 8.69% and a negative net margin of 6.06%. The firm had revenue of $21.90 million during the quarter, compared to analyst estimates of $22.15 million. During the same period last year, the company earned ($0.02) earnings per share. The business’s revenue for the quarter was up 4.8% on a year-over-year basis. Equities research analysts anticipate that STAAR Surgical will post ($0.11) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “STAAR Surgical Company (STAA) Lowered to Hold at Zacks Investment Research” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://www.thecerbatgem.com/2017/09/22/staar-surgical-company-staa-lowered-to-hold-at-zacks-investment-research.html.
Large investors have recently bought and sold shares of the stock. Virtu KCG Holdings LLC bought a new stake in STAAR Surgical during the second quarter valued at $118,000. Goldman Sachs Group Inc. bought a new stake in STAAR Surgical during the first quarter valued at $111,000. Stephens Inc. AR boosted its stake in STAAR Surgical by 2.6% during the second quarter. Stephens Inc. AR now owns 12,238 shares of the medical instruments supplier’s stock valued at $132,000 after buying an additional 315 shares during the period. Simplex Trading LLC boosted its stake in STAAR Surgical by 1,798.8% during the second quarter. Simplex Trading LLC now owns 12,779 shares of the medical instruments supplier’s stock valued at $138,000 after buying an additional 12,106 shares during the period. Finally, Raymond James Financial Services Advisors Inc. bought a new stake in STAAR Surgical during the second quarter valued at $214,000. 76.54% of the stock is owned by institutional investors.
STAAR Surgical Company Profile
STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery.
Receive News & Stock Ratings for STAAR Surgical Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical Company and related stocks with our FREE daily email newsletter.